ISAB and Astra Zeneca: New in vitro paper
A new paper from ISAB and Astra Zeneca shows how DissolvIt simulates the dissolution and absorption of dry powder aerosols in the lung. The paper describes successful in vitro models of PK profiles for budesonide and fluticasone propionate.
“Our new joint paper with Astra Zeneca adds to the evidence that this is a highly accurate, animal-free method that uses just very small amounts of costly test substance, and helps Drug Developers eliminate Candidate Drugs early on. ” says ISAB’s in vitro manager Maria Malmlöf.
ISAB’s CEO Fredrik Sjövall agrees: “The inhaled pharma sector is growing ever more aware just how much time and money can be saved by accurate in vitro testing early on. These are important findings. King’s College London called our in vitro capabilities ‘world-leading’, we’re delighted Astra Zeneca has collaborated as fellow inhalation pioneers too.”
How does it work?
DissolvIt simulates the air-blood barrier of the lung’s upper airways by depositing ‘airborne’ particles on a glass cover slip. ISAB’s dry powder exposure system PreciseInhale aerosolizes and deposits the test formulations onto the cover slips. The simulated barrier consists of a mucus simulant, a polycarbonate membrane and a pumped albumin buffer.
The particle dissolution is observed by optical microscopy. Solute from the dissolving particles diffuses through the barrier and is absorbed into the perfusate. The drug concentration in the perfusate over time, and the remaining drug in the barrier, is measured using liquid chromatography–tandem mass spectrometry. The results are presented as pharmacokinetic graphs with Cmax and tmax.
To read more about DissolvIt visit here.
To read the paper visit here.